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Commentary main text: 
 
Metabolic conditions, such as diabetes and obesity, are major global health problems, with an 
increasing incidence and a significant burden on global healthcare. With diabetes and obesity comes 
a significantly higher risk of developing cardiovascular disease (CVD), which in turn is a major cause 
of morbidity and mortality among those individuals. As such, there is a pressing need to develop new 
treatment options which requires a better understanding of disease mechanisms and the 
identification of novel drug targets. 
Fatty acids have a well-recognised role in metabolic diseases such as diabetes. As well as being a 
critical energy source, they act as ligands for Free Fatty acid receptors (FFARs); a group of G protein-
coupled receptors, which mediate cellular signalling effects of fatty acids. One such receptor, FFAR4 
(also known as GPR120), has been highlighted as essential in maintaining metabolic homeostasis; 
with insulin-sensitising and anti-inflammatory roles as well as controlling adipogenesis (1). As a 
receptor for long-chain fatty acids (LCFAs), FFAR4 has been shown to mediate some of the protective 
and beneficial cell signalling effects of omega-3 fatty acids (1,2).  
In their article, Stuttgen and Sahoo (3) highlight the potential role of FFAR4 in the pathogenesis of 
cardiometabolic disease, noting that while there is extensive evidence of an involvement of FFAR4 in 
metabolic and inflammatory disease (including type 2 diabetes and obesity); the role of FFAR4 in the 
development of atherosclerosis and CVD is only recently emerging. Given the long-standing 
associations between FFAR4/GP120 and obesity, diabetes and inflammation; and the considerable 
interest in developing therapeutic FFAR4 agonists (4), it is surprising that the role of FFAR4 in 
atherosclerosis and CVD (particularly in the context of metabolic disease) is not more well studied. 
Their article (3) follows a recent publication which reports a cardioprotective role for FFAR4 in 
models of pressure overload and associations between the R270H polymorphism (affecting Ga/q 
signalling capacity) and eccentric remodelling in patient cohorts (5). Of note, this FFAR4 variant has 
previously been associated with an increased risk of obesity in European populations (6), though this 
association has not been consistently observed in different study populations (7) and the loss of 
FFAR4 expression or activity alone may not be sufficient to induce obesity. The important question 
also remains as to whether such FFAR4 variants increase the susceptibility to CVD in obese or 
diabetic individuals.  
Another interesting consideration is whether FFAR4 activity could explain at least some of the 
cardioprotective effects of LCFAs (for example omega-3), similarly to the effects observed in 
diabetes, insulin resistance and inflammation (1,2), and whether variations in FFAR4 could account 
for some of the inconsistencies between association studies of LCFAs and CVD. Of course, LCFAs 
have multiple biological roles in addition to FFAR4 agonism, and further mechanistic studies are 
required to untangle the potential cardioprotective effects of LCFAs that are mediated by FFAR4. 
Mechanistically, it seems likely that the involvement of FFAR4 in cardiometabolic disease is at least 
in part due to the role in modulating vascular inflammation. As detailed by Stuttgen and Sahoo (3) 
there are several lines of evidence supporting a role for FFAR4 in regulating macrophage activation; 
one of the beneficial effects of FFAR4 agonists reported in pre-clinical models is in improving chronic 


















potentially makes FFAR4 activation an attractive target for treating vascular damage, atherosclerosis 
and CVD, which are driven by chronic, low-grade inflammation. Indeed, there is also evidence that 
FFAR4 can limit monocyte-endothelial interactions (3). Though there is again some contradictory 
evidence for this role; in a study of FFAR4 in leukocytes, it was concluded that activation by 
polyunsaturated FAs had no effect in an animal model of atherosclerosis (8). In this instance it is 
important to note that the concentrations of FAs were comparatively much lower than those in 
other studies (1,2) and, crucially, the level of FFAR4 activation achieved by these FAs will not 
necessarily be comparable to the chronic and consistent FFAR4 activation possible with synthetic 
agonists. Further detailed studies using small-molecule FFAR4 agonists in pre-clinical models of 
atherosclerosis and CVD are therefore warranted.     
Important sex-specific differences in the role of FFAR4 have also been noted (3), requiring further 
investigation and consideration in future studies. It will also be important to delineate the tissue- 
and cell-specific effects of FFAR4 activation, as the potential roles in chemoresistance and survival of 
certain cancers (3) suggests therapies based on activating FFAR4 may not always be beneficial. 
As discussed by Stuttgen and Sahoo (3), there is a compelling case for a role of FFAR4 in 
cardiometabolic disease and there is clearly great potential for FFAR4 to be targeted therapeutically. 
Overall, pre-clinical studies investigating the effects of FFAR4 agonism in obesity, diabetes and 
inflammation are promising, but there is a distinct lack of research investigating the role of FFAR4 in 
atherosclerosis and CVD; leaving many important questions remaining. It seems variations in FFAR4 
(including a loss of activity and expression) could play a role in susceptibility to cardiometabolic 
diseases and there is the potential that increasing FFAR4 activation could be protective; but further 
comprehensive studies, with a triangulation of findings from in vitro systems and pre-clinical models 
to larger population-based studies, are needed. Such future work will no doubt shed light on the 
mechanistic roles of FFAR4 in atherosclerosis and CVD and subsequently, whether FFAR4 agonism 
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